NEOS Investment Management LLC Has $19.01 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

NEOS Investment Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 35.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 205,829 shares of the biopharmaceutical company’s stock after buying an additional 53,891 shares during the period. NEOS Investment Management LLC’s holdings in Gilead Sciences were worth $19,012,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Southland Equity Partners LLC grew its stake in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 110 shares during the last quarter. Berkshire Bank lifted its holdings in Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 111 shares during the period. CFO4Life Group LLC grew its position in shares of Gilead Sciences by 2.7% in the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 112 shares during the last quarter. GHP Investment Advisors Inc. raised its position in shares of Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock worth $1,049,000 after acquiring an additional 122 shares during the last quarter. Finally, J.W. Cole Advisors Inc. lifted its stake in shares of Gilead Sciences by 1.0% in the fourth quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company’s stock worth $1,256,000 after acquiring an additional 135 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $109.27 on Thursday. The company has a market cap of $136.08 billion, a PE ratio of 295.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business has a 50 day moving average price of $104.69 and a 200-day moving average price of $94.46. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.89%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 302,785 shares of company stock worth $30,503,250 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GILD. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.